Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A gene therapy called ER-100 is showing early promise in restoring vision for glaucoma patients. In a small phase 1 trial, two of three patients who received a single intravitreal injection showed meaningful visual field improvements — with no adverse events. The therapy works by using Nobel Prize-winning "Yamanaka factors" to rejuvenate aging retinal cells rather than replace them.
A gene therapy called ER-100 (Life Biosciences) is generating significant interest in the ophthalmology community. Presented at Eyecelerator@AAO in October 2026, early phase 1 data suggest that a single intravitreal injection — followed by an 8-week course of doxycycline — may help restore visual field in patients with open-angle glaucoma. The therapy harnesses three of the four Nobel Prize-winning "Yamanaka factors" (Oct3/4, Sox2, and Klf4) to partially reprogram retinal ganglion cells back to a younger, healthier state without fully reverting them to stem cells.
The science traces back to a landmark 2006 discovery showing that mature cells can be reprogrammed to a pluripotent state, and later refined at Harvard to restore vision in aging and glaucomatous mice. Life Biosciences — co-founded by Harvard geneticist David Sinclair — is now translating that research into human trials in partnership with Mass Eye and Ear and Columbia's Harkness Eye Institute.
By the Numbers:
Why it matters: Glaucoma-related vision loss is largely irreversible with current treatments. ER-100 doesn't aim to replace dead retinal cells — it revitalizes sick or struggling ones, offering a potential new frontier for patients who previously had little hope for vision recovery.
